Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

  • Exchange: Xetra
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Specialty Pharma

FYB:GR

27.610 EUR 0.220 0.80%

As of 11:36:12 ET on 05/22/2015.

Snapshot for Formycon AG (FYB)

Open: 27.600 Day's Range: 27.030 - 28.880 Volume: 34,589
Previous Close: 27.390 52wk Range: 6.230 - 35.000 1-Yr Rtn: +299.97%

Stock Chart for FYB

No chart data available.
  • FYB:GR 27.665
  • 1D
  • 1M
  • 1Y
27.390
Interactive FYB Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for FYB

Current P/E Ratio (ttm) 294.0644
Estimated P/E(12/2015) 251.0000
Relative P/E vs. DAX 15.4483
Earnings Per Share (EUR) (ttm) 0.0939
Est. EPS (EUR) (12/2015) 0.1100
Est. PEG Ratio -
Market Cap (M EUR) 250.22
Shares Outstanding (M) 9.06
30 Day Average Volume 38,435
Price/Book (mrq) 16.1515
Price/Sale (ttm) 21.0715
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 03/30/2016
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for FYB

  • Revenue
  • Net Income (M/EUR)
  • Profit Margin (%)

Company Profile & Key Executives for FYB

Formycon AG is a biopharmaceutical company with more than twelve years experience in product development. The company's activities focus on developing and marketing "biosimilars" - biopharmaceuticals which are similar to existing drugs for which patent protection is expiring - as well as the provision of contract services to other biotechnology and pharmaceutical companies.

Carsten BrockmeyerChairman-Mgmt Board/CEONicolas CombeCFO/Member-Mgmt Board
More Company Profile & Key Executives for FYB

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil